- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.S3837
| Related Targets | PD-1/PD-L1 CXCR STING AhR CD markers Interleukins Anti-infection Antioxidant COX Histamine Receptor |
|---|---|
| Other Immunology & Inflammation related Products | Cl-amidine Tempol Anti-mouse CD8α-InVivo Tranilast Sinomenine Geniposidic acid GI254023X (GI4023) CORM-3 Bestatin (Ubenimex) Acacetin |
|
In vitro |
DMSO
: 94 mg/mL
(198.85 mM)
|
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 472.70 | Formula | C30H48O4 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 510-30-5 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | CC1(CCC2(C(C1)C3=CCC4C5(CCC(C(C5CCC4(C3(CC2O)C)C)(C)C)O)C)C(=O)O)C | ||
| In vitro |
Echinocystic acid (EA) could induce apoptosis in human HepG2 cells, as characterized by DNA fragmentation, activation of caspase-3, -8, and -9, and PARP cleavage. EA induces the truncation of Bid protein and reduction of Bcl-2 protein. EA also causes the loss of mitochondrial membrane potential (DWm) and cytochrome c release from mitochondria to cytosol. Moreover, EA could activate c-Jun NH2-terminal kinase (JNK) and p38 kinase, and JNK-specific inhibitor SP600125 and p38 kinase-specific inhibitor SB200235 could block serial molecular events of EA-induced apoptosis such as Bid truncation, Bcl-2 reduction, cytochrome c release, caspase activation, and DNA fragmentation in HepG2 cells. EA inhibits HepG2 cell proliferation in a dose-dependent manner with an IC50 value of 45.4 μM at 24h treatment.
|
|---|---|
| In vivo |
Administration of Echinocystic acid (EA) is found to improve the maximum stress and Young’s modulus of femur in OVX rats. Micro-computed tomography analysis reveals that EA could improve the trabecular architecture, as shown by increasing the BV/TV, Tb.N, and Tb.Th in OVX rats. However, EA does not affect the body weight and uterine weight. EA has been shown to display an anti-inflammatory effect in different models of chronic inflammation in mice through the down-regulation of pro-inflammatory cytokines such as IL-1β, IL-18, TNF-α. EA attenuates reserpine-induced pain/depression dyad partially through regulating the biogenic amines levels and GluN2B receptors in the hippocampus.
|
References |
|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.